MIM
CASI

MetLife Investment Management’s CASI Pharmaceuticals CASI Stock Holding History

MetLife Investment Management’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,632
Closed -$106K – 2573
2018
Q4 		$106K Hold
2,632
– – ﹤0.01% 2278
2018
Q3 		$123K Hold
2,632
– – ﹤0.01% 2331
2018
Q2 		$217K Buy
+2,632
New +$178K ﹤0.01% 1890

Other funds holding CASI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $666M AUM 45.43% 1-Year Est. Return
WSC
Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

MetLife Investment Management's CASI Position: Q1 2019 in Review

MetLife Investment Management sold out of CASI Pharmaceuticals (CASI) in Q1 2019, closing a stake of 2,632 shares — an estimated $106K sold.

MetLife Investment Management first reported a position in CASI in Q2 2018 and held it in 3 quarters. The position peaked at $217K in Q2 2018. 52 funds tracked by Wall St. Rank hold CASI as of Q1 2019.

  • MetLife Investment Management reported no remaining CASI Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • MetLife Investment Management sold 2,632 CASI Pharmaceuticals shares in Q1 2019, an estimated $106K.
  • MetLife Investment Management first reported a position in CASI Pharmaceuticals in Q2 2018 and held it in 3 quarters.
  • MetLife Investment Management's CASI Pharmaceuticals position peaked at $217K in Q2 2018.
  • 52 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q1 2019.

Based on MetLife Investment Management's 13F filing for Q1 2019, filed 15 May 2019.